Olema Pharmaceuticals, Inc. cotiza a 7.02 USD y tiene una capitalización bursátil de $614M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical tri…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.61 | $-0.52 | $-0.50 |
| Estimado | $-0.63 | $-0.56 | $-0.54 | $-0.53 |
| Sorpresa | — | -8.9% | +3.7% | +5.7% |
| Métrica | OLMA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -34.0% | -40.4% | +6.4% |
| ROA | -30.4% | -32.0% | +1.6% |
| Current Ratio | 9.95 | 2.84 | +7.11 |
| Debt / Equity | — | 0.28 | — |